PDF   Print   View All
March 06, 2003
Hemispherx Biopharma to Present New Interim Clinical Data Regarding Phase IIB Study in HIV/AIDS at the 16th International Conference on Antiviral Research
Philadelphia, PA, Thursday, March 06, 2003: Hemispherx Biopharma Inc. (Amex: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today that the Company will be giving an oral presentation of its new interim clinical data regarding its Phase IIb Trial for HIV/AIDS (labeled Structured Treatment Interruption) at the 16th International Conference on Antiviral Research on Monday, April 28, 2003 at 11:15 am, EST, at the Savannah Marriott Riverfront Hotel in Savannah, Georgia (April 27-May 1, 2003).

Dr. William M. Mitchell, M.D., PhD. will present the abstract entitled "A Phase IIB Prospective, Randomized, Controlled Study Evaluating Ampligen during Structured Treatment Interruption (STI) of HAART in HIV Infection." The presentation will discuss new interim results from the ongoing study, AMP 720.

Dr. William Carter, commenting on the upcoming presentation, stated, "We are excited to present our new data as it relates to the AIDS pandemic. We also have been notified that the abstract has been selected by the conference organization for expanded coverage. This shows continued interest and confidence in our science and the potential solutions is has to offer in regards to the current global AIDS crisis."

Currently, clinical research sites in the U.S., located in California, Connecticut, Florida (2 sites), New Jersey, New York, Pennsylvania and the District of Columbia (Washington, D.C.), are running the Phase IIb clinical trial testing the efficacy of Ampligen® as a viable STI. During STI, patients have their antiviral therapy (HAART) discontinued, or "interrupted," and Ampligen® is substituted. The Company believes that by interrupting treatment and introducing Ampligen®, the patient can maintain "undetectable levels of virus," as dictated by the Roche Amplicor Assay, while being at far less risk of experiencing multi-drug resistance due to viral mutations in addition to the severe, long-term toxicity inherent with antiviral therapy.

Earlier data presented at the Drug Development in Antiretroviral Research (DART) Conference on December 17, 2002, suggested a median of more than 15 weeks off HAART with no significant viral rebound for the Ampligen group, compared with 7 weeks for the placebo group.

More details on the Ampligen® clinical study design, therapeutic end points and product safety parameters may be obtained from the U.S. Governmental web site: http://www.clinicaltrials.gov

About The 16th International Conference on Antiviral Research

The 16th International Conference on Antiviral Research (http://www.isar-icar.com) provides an interdisciplinary forum at which investigators involved in basic, applied and clinical research worldwide can meet to review the latest developments in all areas of antiviral research.

About Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc., Philadelphia, PA, is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS). For more information, please visit the Company's website at http://www.hemispherx.net .


Contact(s):
Hemispherx Biopharma, Inc., Investor Relations
Dianne Will, (518) 398-6222, Fax: (518) 398-6223

Wesley Stanton, MRB Investor Relations
(212) 495-0200, Fax: (212) 495-0746

HEB's Web Site: www.hemispherx.net


Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries, and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.